Guerbet's innovation, Eluciremâ„¢ is the first gadolinium-based contrast agent approved at half dose of gadolinium, and with ...
Bracco, a global leader in diagnostic imaging, today announced that the U.S. Food and Drug Administration (FDA) has approved ...
In the U.S., Elucirem is indicated in adults and now in pediatric patients including term neonates, for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal ...